Integrated safety and efficacy of garadacimab for hereditary angioedema prophylaxis across 3 clinical trials: phase 2, pivotal phase 3, and open- label extension studies

被引：0
|
作者：
Magerl, M. [1 ,2 ]
Craig, T. J. [3 ]
Anderson, J. [4 ]
Jacobs, J. S. [5 ]
Tachdjian, R. [6 ]
Farkas, H. [7 ]
Yang, W. H. [8 ]
Staubach, P. [9 ]
Aygoeren-Puersuen, E. [10 ]
Ohsawa, I. [11 ]
Pollen, M. [12 ]
Lawo, J. -P. [13 ]
Bica, M. A. [13 ]
Jacobs, I. [12 ]
机构：
[1] Charite Univ Med Berlin, Inst Allergol, Berlin, Germany
[2] Fraunhofer Inst Translat Med & Pharmacol ITMP Immu, Berlin, Germany
[3] Penn State Univ, Dept Med & Pediat, Allergy Asthma & Immunol, Hershey, PA USA
[4] AllerVie Clin Res, Birmingham, AL USA
[5] Allergy & Asthma Clin Res, Walnut Creek, CA USA
[6] Univ Calif Los Angeles, Div Allergy & Clin Immunol, David Geffen Sch Med, Los Angeles, CA USA
[7] Semmelweis Univ, Hungarian Angioedema Ctr Reference & Excellence, Dept Internal Med & Haematol, Budapest, Hungary
[8] Univ Ottawa, Ottawa Allergy Res Corp, Ottawa, ON, Canada
[9] Univ Med Ctr Mainz, Dept Dermatol & Allergy, Mainz, Germany
[10] Univ Hosp Frankfurt, Dept Children & Adolescents, Frankfurt, Germany
[11] Saiyu Soka Hosp, Dept Nephrol, Saitama, Japan
[12] CSL Behring, King Of Prussia, PA USA
[13] CSL Behring Innovat GmbH, Marburg, Germany
来源：
ALLERGOLOGIE | 2024年 / 47卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P2.9
引用
收藏
页数：55
相关论文
共 50 条
  • [11] Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study
    Hide, Michihiro
    Ohsawa, Isao
    Nurse, Christina
    Yu, Ming
    JOURNAL OF DERMATOLOGY, 2023, 50 (11): : 1381 - 1391
  • [12] Garadacimab protects against hereditary angioedema attacks from Week 1 in pivotal Phase 3 VANGUARD study
    Aygoeren-Puersuen, E.
    Tachdjian, R.
    Li, H.
    Hsu, C.
    Hakl, R.
    Staubach, P.
    Wieman, L.
    Lawo, J. -P.
    Keith, P. K.
    ALLERGOLOGIE, 2024, 47 (09)
  • [13] GARADACIMAB PROTECTS AGAINST HEREDITARY ANGIOEDEMA ATTACKS FROM WEEK 1 IN PIVOTAL PHASE 3 VANGUARD STUDY
    Tachdjian, R.
    Li, H.
    Hsu, C.
    Hakl, R.
    Staubach, P.
    Wieman, L.
    Lawo, J.
    Keith, P.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S27 - S28
  • [14] LONG-TERM QUALITY-OF-LIFE AND PATIENT-REPORTED IMPROVEMENTS WITH GARADACIMAB FOR HEREDITARY ANGIOEDEMA: PHASE 3 OPEN-LABEL EXTENSION STUDY
    Braverman, J.
    Chapdelaine, H.
    Sitz, K.
    Katelaris, C.
    Guilarte, M.
    Longhurst, H.
    Lawo, J.
    Lumry, W.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S39 - S39
  • [15] Evaluation of icatibant for the repeated treatment of hereditary angioedema attacks across three phase III open label extension studies
    Aberer, W.
    Lumry, W.
    Farkas, H.
    Bernstein, J. A.
    Bouillet, L.
    Baptista, J.
    Reidl, M.
    ALLERGY, 2013, 68 : 16 - 16
  • [16] Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open-label study
    Hide, Michihiro
    Wang, Yi
    Dote, Nobuhito
    Miyakawa, Kou
    Sugiura, Kenkichi
    Ishida, Kazuyuki
    JOURNAL OF DERMATOLOGY, 2023, 50 (11): : 1473 - 1477
  • [17] Efficacy and Safety of Subcutaneous Garadacimab for the Prophylaxis of Hereditary Angioedema Attacks in Adults and Adolescent Patients with HAE: Results from a Multicenter, Placebo-Controlled Phase 3 Trial
    Craig, Timothy
    Magerl, Markus
    Reshef, Avner
    Li, Huamin
    Jacobs, Joshua
    Bernstein, Jonathan
    Farkas, Henriette
    Yang, William
    Stroes, Erik
    Ohsawa, Isao
    Tachdjian, Raffi
    Manning, Michael
    Lumry, William
    Saguer, Inmaculada Martinez
    Aygoeren-Puersuen, Emel
    Ritchie, Bruce
    Sussman, Gordon
    Anderson, John
    Kawahata, Kimito
    Suzuki, Yusuke
    Staubach, Petra
    Treudler, Regina
    Feuersenger, Henrike
    Wieman, Lolis
    Jacobs, Iris
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB132 - AB132
  • [18] Long-term quality-of-life and patient-reported improve-ments with garadacimab for hereditary angioedema: Phase 3 open-label extension study
    Aygoeren-Puersuen, E.
    Chapdelain, H.
    Sitz, K.
    Katelaris, C. H.
    Staubach, P.
    Magerl, M.
    Saguer, I. Martinez
    Guilarte, M.
    Longhurst, H.
    Lawo, J. -P
    Braverman, J.
    Lumry, W. R.
    ALLERGOLOGIE, 2024, 47 (09)
  • [19] PHASE 2 OPEN-LABEL EXTENSION STUDY WITH DONIDALORSEN TREATMENT IN PATIENTS WITH HEREDITARY ANGIOEDEMA
    Bordone, L.
    Riedl, M.
    Newman, K.
    Lui, C.
    Alexander, V.
    Schneider, E.
    Cohn, D.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S33 - S33
  • [20] A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema
    Petersen, Remy S.
    Bordone, Laura
    Riedl, Marc A.
    Tachdjian, Raffi
    Craig, Timothy J.
    Lumry, William R.
    Manning, Michael E.
    Bernstein, Jonathan A.
    Raasch, Jason
    Zuraw, Bruce L.
    Deng, Yiwen
    Newman, Kenneth B.
    Alexander, Veronica J.
    Lui, Cindy
    Schneider, Eugene
    Cohn, Danny M.
    ALLERGY, 2024, 79 (03) : 724 - 734
12345